SynGen Inc., a company that focuses on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, announced today that it has appointed David Hodl, formerly Business Development Manager for Becton Dickinson, to lead commercialization efforts for the newly formed Cell Processing Business Unit.
David brings 19 years of experience in product commercialization and business development in the life science and medical products industry. During his tenure with BD’s Corporate Innovation Center, he led the commercialization of several cell-based technologies, including BD FACS CAP™, an antibody-based cell surface marker profiling platform and BD’s Discovery Platform, a custom cell culture environment development service. He also played a leading role in executing the development partnership between BD and Fate Therapeutics to access proprietary technology for developing products for expansion and differentiation of induced pluripotent stem cells.
“We are very excited about bringing David on board,” said William Gerber, SynGen’s President and Chief Executive Officer. “David‘s experience, reputation, skills and insight are exactly what we need as we continue to grow our product lines, and move into the Cell Processing Market.”
About SynGen’s Cell Processing Instrumentation Product Line:
- SynGenX™-Lab System: The SynGenX-Lab System is designed for the efficient extraction of target cell populations from bone marrow or blood samples in a closed, sterile device, and was designed for use in cell processing laboratories. The system provides flexibility in the processing of high-value cells and enables cell harvesting, cell washing, volume reduction/concentration, and cell separation without Ficoll. The SynGenX-Lab provides high recovery rates and viability of target cell populations.
- WashPRO™ System: The WashPRO System is a new product that enables further automation of the cell washing process, with recoveries of over 90% after multiple wash cycles, with minimal loss of cell viability. Integrated temperature and mass sensors provide process data for cGMP-compliant records. This system will be ready for beta testing at select sites in the spring of 2015.
To download a copy of this press release, please click here.